"Jerky" dystonia in children: spectrum of phenotypes and genetic testing

Mov Disord. 2009 Apr 15;24(5):702-9. doi: 10.1002/mds.22426.

Abstract

Hyperkinetic dystonia is characterized by phasic, tremulous, and "jerky" movements in addition to twisting postures. We studied longitudinally 23 index patients with hyperkinetic dystonia from a quaternary pediatric movement disorder clinic in Ireland. Four clinical categories emerged: (1) Eight patients were diagnosed with myoclonus-dystonia, of whom seven carried heterozygous epsilon sarcoglycan (SGCE) mutations, including a novel deletion of exon 10. Gait disorder, unsteadiness, or frequent falls before 18 months were detected in all SGCE mutation carriers, whereas the typical neck-predominant presentation developed only years later. (2) One patient classified as benign hereditary chorea, because jerks were choreiform and continuous rather than action-induced, carried a heterozygous stop mutation of the TITF-1 gene (Y114X, exon 2). (3) Three mutation-negative patients were grouped as "myoclonic dystonia" with jerks only in the body regions affected by dystonia. (4) Eleven patients presented with a novel combination of dystonia and low amplitude poly-mini myoclonus of the upper limbs and pectoral muscles (D-PMM). In early childhood up to 3 years of age, an initial presentation with predominant gait impairment with only subtle jerks should prompt consideration of SGCE mutation analysis in addition to testing for DYT1 mutations. A causative gene for D-PMM remains to be identified.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Age of Onset
  • Anticonvulsants / therapeutic use
  • Antiparkinson Agents / therapeutic use
  • Child
  • Child, Preschool
  • DNA Mutational Analysis
  • Dystonia / complications*
  • Dystonia / diagnosis
  • Dystonia / drug therapy
  • Dystonia / genetics*
  • Exons
  • Female
  • Genetic Testing
  • Genotype
  • Humans
  • Hyperkinesis / complications*
  • Hyperkinesis / diagnosis
  • Hyperkinesis / drug therapy
  • Hyperkinesis / genetics*
  • Levodopa / therapeutic use
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Muscle, Skeletal / physiopathology
  • Mutation / genetics
  • Myoclonus / genetics
  • Myoclonus / physiopathology
  • Nuclear Proteins / genetics
  • Phenotype*
  • Sarcoglycans / genetics*
  • Severity of Illness Index
  • Thyroid Nuclear Factor 1
  • Transcription Factors / genetics
  • Tyrosine / genetics
  • Young Adult

Substances

  • Anticonvulsants
  • Antiparkinson Agents
  • Nuclear Proteins
  • SGCG protein, human
  • Sarcoglycans
  • Thyroid Nuclear Factor 1
  • Transcription Factors
  • Tyrosine
  • Levodopa